Home  |  Contact

UniProtKB/Swiss-Prot P10636: Variant p.Gly590Arg

Microtubule-associated protein tau
Gene: MAPT
Variant information

Variant position:  590
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Arginine (R) at position 590 (G590R, p.Gly590Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In FTD; increased aggregation propensity and altered binding affinity towards microtubules and F-actin.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  590
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  758
The length of the canonical sequence.

Location on the sequence:   LKNVKSKIGSTENLKHQPGG  G KVQIINKKLDLSNVQSKCGS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGS

Gorilla                       LKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGS

Rhesus macaque                LKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGS

Chimpanzee                    LKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGS

Mouse                         LKNVRSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGS

Rat                           LKNVRSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGS

Bovine                        LKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGS

Goat                          LKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGS

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 758 Microtubule-associated protein tau
Repeat 561 – 591 Tau/MAP 1
Region 561 – 685 Microtubule-binding domain
Site 571 – 571 Not glycated
Site 574 – 574 Not glycated
Site 584 – 584 Not glycated
Site 591 – 591 Not glycated
Site 607 – 607 Not glycated
Modified residue 576 – 576 N6-acetyllysine; alternate
Modified residue 576 – 576 N6-methyllysine; alternate
Modified residue 579 – 579 Phosphoserine; by MARK1, MARK2, MARK3, MARK4, BRSK1, BRSK2 and PHK
Modified residue 596 – 596 Deamidated asparagine; in tau and PHF-tau; partial
Modified residue 598 – 598 N6-acetyllysine; alternate
Modified residue 602 – 602 Phosphoserine; by PHK
Modified residue 607 – 607 N6-acetyllysine
Modified residue 610 – 610 Phosphoserine
Glycosylation 576 – 576 N-linked (Glc) (glycation) lysine; in PHF-tau; in vitro
Glycosylation 597 – 597 N-linked (Glc) (glycation) lysine; in PHF-tau; in vitro
Glycosylation 598 – 598 N-linked (Glc) (glycation) lysine; in PHF-tau; in vitro
Cross 571 – 571 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); in PHF-tau
Cross 576 – 576 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Cross 584 – 584 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Cross 598 – 598 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Mutagenesis 579 – 579 S -> A. 8% decrease in microtubule-binding after in vitro phosphorylation of mutant protein.
Beta strand 587 – 590


Literature citations

Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R.
Sandberg A.; Ling H.; Gearing M.; Dombroski B.; Cantwell L.; R'Bibo L.; Levey A.; Schellenberg G.D.; Hardy J.; Wood N.; Fernius J.; Nystroem S.; Svensson S.; Thor S.; Hammarstroem P.; Revesz T.; Mok K.Y.;
Neurobiol. Dis. 146:105079-105079(2020)
Cited for: VARIANT FTD ARG-590; CHARACTERIZATION OF VARIANT FTD ARG-590; FUNCTION;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.